Melasma Drugs: What Causes It and What Actually Treats It

What Exactly Is Melasma and Why Does It Target Women?

Melasma is a chronic disorder of excess melanin production that creates symmetrical brown or grey-brown patches, most commonly across the cheeks, forehead, upper lip, and chin. It is not dangerous, but it is persistent and deeply affects quality of life.

Women account for approximately 90% of all melasma cases, a figure that points directly to the role of female sex hormones in driving the condition. Estrogen and progesterone both stimulate melanocytes, the pigment-producing cells in the skin, and any hormonal fluctuation can activate them.

The three main triggers are ultraviolet radiation, hormonal shifts, and genetic predisposition. In women, those three factors collide repeatedly across a lifetime, during pregnancy, while on the pill, during perimenopause, and when using hormone therapy. That is why understanding melasma through a women's-health lens is not optional. It is the only lens that fully explains the condition.

How Melanocytes Respond to Estrogen

Melanocytes carry estrogen receptors. When estrogen levels rise, whether from pregnancy, oral contraceptives, or hormone therapy, these receptors signal the cells to increase melanin synthesis. Research published in the Journal of the American Academy of Dermatology has confirmed estrogen receptor expression in melasma-affected skin, which is why the condition tracks so closely with hormonal exposure.

UV light compounds the problem by independently activating melanocytes and by upregulating local estrogen production in the skin itself. Sun exposure without hormonal trigger can worsen existing melasma and often causes relapse after successful treatment.

Which Skin Types Are Most Vulnerable?

Women with Fitzpatrick skin types III through VI (olive, brown, or dark skin tones) have a higher baseline melanocyte activity, which means hormonal or UV triggers produce a more pronounced pigmentary response. Studies estimate worldwide melasma prevalence at 1% to 50% depending on population, with the highest rates in Latin American, South Asian, Southeast Asian, and Middle Eastern women.

Drugs That Cause or Worsen Melasma

Several classes of medication directly trigger or aggravate melasma, and identifying the culprit in your own regimen is the first clinical step.

Hormonal Contraceptives

Combined oral contraceptives (COCs) containing ethinyl estradiol are the most commonly implicated drug class. A 2019 review in the International Journal of Women's Dermatology confirmed that estrogen-containing contraceptives significantly increase melasma risk, with onset typically occurring within the first three to six months of use.

Progestin-only pills (the "mini-pill") carry a lower but non-zero risk. The levonorgestrel IUD releases very low systemic progestin levels and is generally considered a lower-risk option for women who develop melasma on combined pills, though data specifically on IUD-associated melasma remain limited. Implants (etonogestrel) have also been reported to trigger melasma in case reports, though systematic evidence is sparse.

If you developed facial pigmentation after starting any hormonal contraceptive, switching to a non-hormonal method (copper IUD, barrier methods) is the only definitive way to remove that hormonal trigger.

Hormone Therapy in Perimenopause and Menopause

Women starting menopausal hormone therapy (MHT) can develop new melasma or experience worsening of existing patches. The risk appears higher with oral estrogen than with transdermal estradiol patches or gels, because oral estrogen produces supraphysiologic first-pass hepatic estrogen metabolites and higher peak serum estrogen levels.

The Menopause Society (formerly NAMS) guidelines do not list melasma as a contraindication to MHT, but they do support individualized decision-making that weighs skin changes alongside vasomotor symptom relief. If you are in perimenopause and your melasma worsened after starting an oral estradiol regimen, discuss a transdermal switch with your clinician.

Photosensitizing Medications

A number of drugs make the skin more reactive to UV light, which then activates melanocytes:

• Tetracycline antibiotics (doxycycline, minocycline): commonly prescribed for acne, but they increase UV sensitivity and can deepen existing melasma
• Phenytoin (an antiepileptic): associated with a drug-specific facial pigmentation sometimes called "phenytoin pigmentation" that overlaps clinically with melasma
• Chlorpromazine and other phenothiazines: produce grey-brown pigmentation, particularly in sun-exposed areas
• Amiodarone: causes a blue-grey discoloration through drug deposition, distinct from true melasma but sometimes confused with it
• Non-steroidal anti-inflammatory drugs (NSAIDs): some evidence links chronic topical NSAID use to pigmentary changes, though the mechanism differs from hormonal melasma

A systematic review in Photodermatology, Photoimmunology and Photomedicine catalogued drug-induced photosensitivity reactions and their pigmentary consequences, noting that any drug classified as a photosensitizer should be used with broad-spectrum SPF 50 sunscreen daily.

Fertility Treatments and Assisted Reproduction

Controlled ovarian stimulation protocols use pharmacologic doses of gonadotropins and often add supplemental progesterone in the luteal phase or early pregnancy. These high-dose hormonal exposures can trigger melasma in women who have never had it before. For women who are trying to conceive and notice new facial pigmentation during an IVF cycle, this is the likely explanation. The pigmentation may fade after the pregnancy or after discontinuing progesterone supplementation, but UV protection is needed to prevent it from fixing permanently.

Drugs and Treatments That Treat Melasma

Treatment works best when it addresses all three drivers simultaneously: depigmentation, UV protection, and (where possible) hormonal source removal.

Topical Depigmenting Agents

Hydroquinone

Hydroquinone is the most studied and most prescribed topical treatment for melasma. It works by inhibiting tyrosinase, the rate-limiting enzyme in melanin synthesis. Prescription-strength hydroquinone 4% applied once or twice daily is the standard starting point.

A landmark 2006 randomized controlled trial published in the Journal of the American Academy of Dermatology demonstrated that a triple-combination cream containing hydroquinone 4%, tretinoin 0.05%, and fluocinolone acetonide 0.01% (sold as Tri-Luma) achieved a complete or near-complete reduction in melasma severity in 77% of participants after eight weeks, significantly outperforming any single agent alone. This triple combination remains a guideline-recommended first-line option.

Hydroquinone should not be used for longer than three to five consecutive months without a break, due to the risk of exogenous ochronosis (a paradoxical blue-black skin darkening) with prolonged high-concentration use.

Tretinoin (Topical Vitamin A)

Tretinoin 0.025% to 0.1% accelerates keratinocyte turnover and interrupts melanin transfer to skin cells. It is often used in combination with hydroquinone rather than as monotherapy. As a standalone, a double-blind trial in the Archives of Dermatology found tretinoin 0.1% reduced melasma area and severity index (MASI) scores significantly more than vehicle, but treatment took 24 weeks.

Tretinoin is contraindicated in pregnancy. See the dedicated pregnancy section below.

Azelaic Acid 20%

Azelaic acid inhibits tyrosinase and selectively targets hyperactive melanocytes without depigmenting normal skin. It is considered safe in pregnancy (Category B). Studies comparing azelaic acid 20% cream to hydroquinone 2% found comparable efficacy with fewer side effects, making azelaic acid the preferred topical agent for pregnant or breastfeeding women.

Kojic Acid and Other Agents

Kojic acid (0.75% to 2%) is a fungal metabolite that inhibits tyrosinase. It is often found in over-the-counter serums and is frequently combined with other agents. Evidence for kojic acid as monotherapy is modest, but it contributes meaningfully in combination products.

Niacinamide (4% to 5%) inhibits melanosome transfer rather than melanin production itself. It is well tolerated, available without a prescription, and safe in pregnancy, though its effect size is smaller than hydroquinone.

Oral Tranexamic Acid: The Emerging First-Line Option

Tranexamic acid (TXA) is an antifibrinolytic drug long used to reduce surgical bleeding. Its mechanism in melasma is different. It blocks the interaction between keratinocytes and melanocytes by inhibiting plasminogen activator, which reduces UV-induced prostaglandin synthesis and thereby suppresses melanocyte stimulation.

A 2020 systematic review and meta-analysis in the Journal of the American Academy of Dermatology analyzed data from 561 patients across 18 studies and found that oral TXA at 250 mg twice daily produced significant MASI score reductions with a favorable safety profile. The most common side effect was mild gastrointestinal discomfort.

The WomanRx clinical framework for oral TXA candidacy in women with melasma:

| Life Stage | TXA Appropriate? | Notes | |---|---|---| | Reproductive years (not pregnant) | Yes, with caution | Avoid in women with personal or family history of VTE or thrombophilia | | Trying to conceive | Not recommended | Insufficient pregnancy safety data; discontinue before conception attempt | | Pregnant | Contraindicated | Crosses placenta; no safety data for cosmetic indication | | Breastfeeding | Not recommended | TXA is excreted in breast milk; avoid | | Perimenopause | Yes, with caution | Check VTE risk factors, especially if on MHT concurrently | | Post-menopause | Yes, with caution | Same VTE assessment needed |

Because TXA does have prothrombotic potential at higher doses (it is used IV at 10-15 mg/kg for surgical hemostasis), all women considering oral TXA for melasma should have a thrombotic risk assessment before starting. Women with prior DVT, PE, stroke, Factor V Leiden, or antiphospholipid antibody syndrome should not use it.

Procedures: Chemical Peels, Lasers, and Light Devices

Superficial chemical peels using glycolic acid (20% to 70%), lactic acid, or salicylic acid remove melanin-laden keratinocytes and can accelerate topical treatment responses. A series of four to six peels at two to four week intervals is typical.

Laser and light-based treatments carry greater risk in women with darker skin tones. Q-switched Nd:YAG laser has the strongest evidence base for Fitzpatrick types IV-VI, but post-inflammatory hyperpigmentation (PIH) is a real risk if the wrong device or fluence is chosen. A comparative study in Lasers in Surgery and Medicine found that low-fluence Q-switched Nd:YAG produced meaningful improvement in Asian women with melasma without significant PIH when combined with topical treatment.

Intense pulsed light (IPL) should be used cautiously in women with Fitzpatrick types IV and above due to the high risk of PIH. Always confirm your provider has specific experience treating your skin tone before booking any energy-based procedure for melasma.

Sunscreen Is a Treatment, Not Just Prevention

This point is worth stating plainly: broad-spectrum SPF 50 sunscreen used daily is a first-line treatment for melasma, not merely a supportive adjunct. A randomized controlled trial in the British Journal of Dermatology showed that daily SPF 50 sunscreen alone produced a meaningful reduction in MASI scores over 24 weeks, comparable to some topical agents.

Mineral sunscreens containing zinc oxide or titanium dioxide provide better protection against visible light (which also stimulates melanocytes in darker skin) than chemical filters alone. For women with Fitzpatrick types IV-VI, iron oxide-containing tinted mineral sunscreens offer additional visible-light protection. Apply every morning and reapply every two hours if outdoors.

Pregnancy, Postpartum, and Lactation: What Is Safe?

This section is required reading if you are pregnant, trying to conceive, or breastfeeding, because most standard melasma treatments carry restrictions.

Pregnancy (Chloasma Gravidarum)

Pregnancy-related melasma (chloasma) affects up to 70 to 90% of pregnant women and typically appears in the second or third trimester when estrogen and MSH (melanocyte-stimulating hormone) levels peak. It often fades within a few months of delivery, particularly if UV exposure is minimized.

Drug safety in pregnancy for melasma:

• Hydroquinone (FDA Category C): Animal data shows no teratogenicity, but systemic absorption through topical use is real (35% absorbed percutaneously), and no adequate controlled studies exist in pregnant women. ACOG and most dermatology guidelines recommend avoiding hydroquinone in pregnancy. Use only if the potential benefit clearly outweighs risk, in discussion with your OB.
• Tretinoin (Category X equivalent, teratogen): Oral retinoids (isotretinoin) are known teratogens. Topical tretinoin has low systemic absorption, but systemic retinoids cause severe birth defects. The general clinical recommendation is to avoid topical tretinoin in pregnancy out of an abundance of caution, as outlined in ACOG guidance on dermatologic conditions in pregnancy.
• Azelaic acid (Category B): Considered the safest prescription topical for melasma in pregnancy. Preferred by most clinicians for pregnant women who want treatment.
• Niacinamide: No pregnancy category assigned (pre-PLLR drug), but considered low-risk given minimal systemic absorption. A reasonable OTC option.
• Oral tranexamic acid: Contraindicated for this cosmetic indication in pregnancy. Crosses the placenta. Not recommended.
• Chemical peels (superficial): Glycolic acid and lactic acid peels are generally considered low-risk in pregnancy because they have minimal systemic absorption, but data are limited and most clinicians defer elective cosmetic procedures until after delivery.

Postpartum and Lactation

After delivery, if you are breastfeeding:

• Hydroquinone: Excreted in breast milk; most clinicians recommend avoiding it or delaying use until after weaning.
• Tretinoin: Topical form has very low systemic levels, but no adequate breastfeeding data exist. Avoid unless your dermatologist or OB specifically recommends otherwise.
• Azelaic acid: Considered compatible with breastfeeding; small amounts present in breast milk naturally as a dietary byproduct.
• Tranexamic acid oral: Excreted in breast milk at low concentrations. Not recommended for the cosmetic treatment of melasma during lactation.

The most important action postpartum is rigorous sun protection. Chloasma that appears in pregnancy frequently fades on its own over three to six months if UV exposure is controlled. Beginning aggressive treatment before allowing that natural resolution may be unnecessary.

Who This Is Right for (and Who Should Think Twice)

Women Who Are Good Candidates for Aggressive Melasma Treatment

• You have been off hormonal contraception for at least three months and melasma persists
• Your pigmentation is causing significant psychological distress or social impact
• You are post-menopause and have ruled out or addressed hormonal triggers
• You have Fitzpatrick type I-III and want laser or peel procedures (lower PIH risk)
• You have no personal or family history of VTE and are considering oral TXA

Women Who Should Approach Treatment More Carefully

• You are currently pregnant (limit to SPF 50 mineral sunscreen plus azelaic acid if needed)
• You are breastfeeding (same conservative approach)
• You are in perimenopause and taking oral estrogen MHT (consider switching to transdermal before starting depigmenting agents)
• You have Fitzpatrick type IV-VI and are considering laser (insist on a provider experienced with your skin tone)
• You have a history of thromboembolism (TXA is not appropriate)
• You are trying to conceive (time your treatment so that tretinoin and TXA are stopped before conception)

Diagnosing Melasma: When to See a Clinician

Melasma is diagnosed clinically, meaning by visual examination, usually without a biopsy. A Wood's lamp (UV light) examination helps determine whether the pigment is in the epidermis (superficial, responds better to topicals) or the dermis (deeper, harder to treat).

Dermoscopy findings characteristic of melasma include a brown pseudoreticular network with follicular sparing, which helps distinguish it from post-inflammatory hyperpigmentation, solar lentigines, or lichen planus pigmentosus.

You should see a dermatologist or clinician rather than self-treating when:

• The pigmentation appeared suddenly or changed rapidly (rule out lentigo maligna)
• You have associated symptoms like itching, bleeding, or tenderness
• The pattern is asymmetric or does not match the classic malar/centrofacial distribution
• Over-the-counter products have not worked after three months of consistent use with sun protection
• You want prescription treatment (hydroquinone 4%, tretinoin, oral TXA) or a procedure

The Recurrence Problem: Why Melasma Keeps Coming Back

Recurrence is the most underappreciated fact about melasma. Even after successful treatment, relapse rates exceed 50% within 12 months if sun protection is discontinued or hormonal triggers are reintroduced. This is not a treatment failure. It reflects the chronic nature of the condition.

The practical implication: melasma management is ongoing, not a one-time course. Many women do well on a maintenance regimen of daily SPF 50 tinted mineral sunscreen, nightly niacinamide, and periodic short courses of hydroquinone or azelaic acid when pigmentation flares. Quarterly check-ins with your clinician help catch early relapse before it deepens.

A 2022 consensus statement on melasma management emphasized that "patient education about the chronic, relapsing nature of melasma and the critical role of photoprotection is as therapeutically important as any pharmacologic intervention." That framing matters. Your sunscreen is your first-line treatment, not your afterthought.